NCAM1 and hematologic disorder: After starting with a leukapheresis product that was depleted for CD3+ cells and enriched for CD56+ cells, cultivation in medium containing IL-2 (1,000 U/mL) for up to 2 weeks yielded 0.1–3 × 109 CD56+CD3− NK cells (Table 1), sometimes sufficient for multiple infusions to patients with hematological malignancies (26).